Areteia Therapeutics Announces Publication of Phase II Data of Oral Dexpramipexole in Eosinophilic Asthma
In the EXHALE-1 study, dexpramipexole significantly reduced blood absolute eosinophil count (AEC) at week 12 versus placebo All three active doses achieved significance (150-mg, 75-mg, and 37.5-mg BID) Dexpramipexole displayed a favorable safety profile and was well tolerated, with 97% … Continued